“We can’t take the orphan drug revolution for granted.“ Biorasi’s Few & Far Between Podcast welcomes Jim Geraghty, author and biotech industry veteran, to discuss the necessity and viability of orphan and rare disease research - for both patients and VC investors alike.
On this week’s Few & Far Between podcast episode, Biorasi’s CEO, Chris O'Brien, welcomes Karen Petrou and David Brint for an in-depth discussion on...
Let's kick off 2026 with the first Biorasi podcast episode of the year! How do you get "Biotech Vision" to see the complete picture...
"We have to rethink the sense of clinical research from the point of view that if we have the possibility to have markers that...